QuickStrip

07/07/2026

$DOSE Extends Strategic Collaboration with Global Ni****ne Leader, Initiates Saudi Arabia Commercialization

Rapid Dose Therapeutics ($DOSE) has announced the extension of its strategic collaboration with a global ni****ne leader through a Memorandum of Understanding (MOU).

The agreement advances the development and commercialization of QuickStrip™ Ni****ne (NicStrip™) while recognizing Saudi Arabia as a distinct commercialization opportunity within the broader collaboration.

Read the full news release:

🔗 https://www.newsfilecorp.com/release/304185

****ne

Burlington, Ontario--(Newsfile Corp. - July 7, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian...

07/01/2026

This Canada Day, we celebrate the innovation, resilience, and entrepreneurial spirit that continue to shape Canada’s life sciences industry.

At Rapid Dose Therapeutics, we are proud to be a Canadian company advancing the future of drug delivery through our proprietary QuickStrip™ oral thin film technology, designed to improve patient experience, accessibility, and healthcare outcomes.

As we continue to innovate and develop novel oral thin film delivery solutions, we remain committed to scientific excellence, patient outcomes, and pushing the boundaries of what’s possible in healthcare.

Today, we celebrate the researchers, healthcare professionals, innovators, partners, and investors who help drive Canadian innovation forward.

From all of us at Rapid Dose Therapeutics, we wish you a safe, happy, and memorable Canada Day.

🇨🇦 Proudly Canadian.
🔬 Science Driven.
❤️ Focused on Patient Outcomes.
💡 Innovating Possibilities.

04/13/2026

Rapid Dose Therapeutics is advancing the next phase of its Burlington facility expansion targeting global medical markets to strengthen pharmaceutical manufacturing capability, support future regulatory pathways, and expand the long-term strategic value of its QuickStrip™ platform.

This is more than a facility upgrade. It is a disciplined investment in infrastructure designed to support scale, flexibility, and future participation in regulated global medical markets.

Why this matters:
• Global prescription drug sales are forecast to reach approximately US$1.7 trillion by 2030.
• The global medical cannabis market is projected to reach approximately US$65.9 billion by 2030.
• As demand grows for compliant, non-combustible, patient-friendly delivery formats, manufacturing readiness becomes a strategic advantage.

https://rapid-dose.com/rapid-dose-therapeutics-cse-dose-otcqb-rdtcf-advances-pharmaceutical-manufacturing-expansion-with-burlington-facility-upgrades-targeting-global-medical-markets/

BURLINGTON, ON — April 13, 2026 — Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) (“RDT” or the “Company”), a Canadian biotechnology company developing oral thin film drug delivery technologies, today announced the initiation of clean room upgrades and facility retrofitting at i...

03/05/2026

Major Patent Milestone!

Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) Secures Patent for QuickStrip™ Ni****ne Oral Film Targeting $38B Smoke-Free Ni****ne Market

Key Highlights for Investors:

• Massive Addressable Market: The global modern oral ni****ne market is projected to reach $38.89 Billion by 2033, growing at a 19% CAGR.

• Global IP Footprint: This grant follows our 2025 WIPO PCT filing, extending potential protection to up to 158 jurisdictions worldwide.

• Strategic Advantage: Partnered with Aavishkar Oral Strips, we are positioned to disrupt traditional ni****ne delivery with a discreet, smoke-free alternative.

• Ongoing Discussions: RDT remains engaged in commercial discussions with a major global ni****ne company, a relationship now backed by stronger IP.

Read the full press release here:
https://rapid-dose.com/rapid-dose-therapeutics-cse-dose-otcqb-rdtcf-secures-patent-for-quickstrip-ni****ne-oral-film-targeting-38b-smoke-free-ni****ne-market/

****neReplacement $DOSE $RDTCF

BURLINGTON, Ontario — March 5, 2026 — Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), a Canadian biotechnology company specializing in oral thin film drug delivery technology, today announced the grant of a key patent for its QuickStrip™ Ni****ne Bilayer Oral Film in partnership with...

02/23/2026

Rapid Dose Therapeutics advances cannabinoid research and clinical evaluation of its proprietary QuickStrip™ oral thin film delivery platform. Independent studies, supported by grant funding, are exploring cannabinoids’ role in pain management and neuroprotection related to concussion and participation in contact sports, while a clinical arm is assessing CBD bioavailability vs traditional oral formats.

https://www.newsfilecorp.com/release/284877

$DOSE $RDTCF

Burlington, Ontario--(Newsfile Corp. - February 23, 2026) - Rapid Dose Therapeutics Corp. ...

02/18/2026

🚨 INVESTOR ALERT: Aegis Research sees $1.00 path for Rapid Dose Therapeutics Corp (CSE: $DOSE | OTCQB: $RDTCF). 80% bioavailability tech + 45% sales growth
Watch: https://youtu.be/nbX0dLxSllM

$DOSE $RDTCF

Overview of Rapid Dose Therapeutics (CSE: DOSE) (OTC: RDTCF) and its proprietary QuickStrip We are not Financial Advisers and Do Your Own Research. Aegis R...